Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.31M Sell
6,575
-964
-13% -$344K 0.73% 36
2025
Q4
$2.47M Sell
7,539
-1,263
-14% -$401K 0.79% 28
2025
Q3
$2.48M Buy
8,802
+380
+5% +$110K 0.84% 20
2025
Q2
$2.35M Buy
8,422
+747
+10% +$212K 0.91% 18
2025
Q1
$2.39M Buy
7,675
+693
+10% +$205K 1% 17
2024
Q4
$1.82M Buy
6,982
+1,137
+19% +$337K 0.78% 22
2024
Q3
$1.84M Buy
5,845
+270
+5% +$88.3K 0.81% 22
2024
Q2
$1.74M Buy
5,575
+418
+8% +$123K 0.84% 26
2024
Q1
$1.47M Buy
+5,157
New +$1.51M 0.73% 30

Other funds holding AMGN

Gen-Wealth Partners's AMGN Position: Q1 2026 in Review

Gen-Wealth Partners reduced its Amgen (AMGN) stake by 13% in Q1 2026, selling an estimated $344K and leaving 6,575 shares worth $2.31M. The position accounts for 0.73% of the portfolio, ranked #36.

Gen-Wealth Partners first reported a position in AMGN in Q1 2024 and has held it in 9 quarters since. The position peaked at $2.48M in Q3 2025. 3,130 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Gen-Wealth Partners held 6,575 shares of Amgen worth $2.31M as of Q1 2026.
  • Gen-Wealth Partners sold 964 Amgen shares in Q1 2026, an estimated $344K.
  • Amgen made up 0.73% of Gen-Wealth Partners's portfolio in Q1 2026, its #36 holding.
  • Gen-Wealth Partners first reported a position in Amgen in Q1 2024 and has held it in 9 quarters since.
  • Gen-Wealth Partners's Amgen position peaked at $2.48M in Q3 2025.
  • 3,130 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Gen-Wealth Partners's 13F filing for Q1 2026, filed 8 May 2026.